EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations

Kamryn E Jones, Shaun L Hayden, Hannah R Meyer iD, Jillian L Sandoz, William H Arata, Kylie Dufrene, Corrado Ballaera, Yair Lopez Torres, Patricia Griffin, Adam M Kaye iD, Sahar Shekoohi iD, Alan D Kaye iD

Current Issues in Molecular Biology · 22.06.2024 · 46 (7) · 6315-6327

DOI: 10.3390/cimb46070377 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 22.06.2024. Verfasst von Kamryn E Jones und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Worldwide, hypertension is the leading risk factor for cardiovascular disease and death. An estimated 122 million people, per the American Heart Association in 2023, have been diagnosed with this common condition. It is generally agreed that the primary goal in the treatment of hypertension is to reduce overall blood pressure to below 140/90 mmHg, with a more optimal goal of 130/80 mmHg. Common medications for treating hypertension include calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and diuretics. CCBs are one of the most widely studied agents and are generally recommended as first-line therapy alone and in combination therapies. This is largely based on the vast knowledge of CCB mechanisms and their minimal side effect profile. CCBs can be separated into two classes: dihydropyridine and non-dihydropyridine. Non-dihydropyridine CCBs act on voltage-dependent L-type calcium channels of cardiac and smooth muscle to decrease muscle contractility. Dihydropyridine CCBs act by vasodilating the peripheral vasculature. For many patients with only mild increases in systolic and diastolic blood pressure (e.g., stage 1 hypertension), the medical literature indicates that CCB monotherapy can be sufficient to control hypertension. In this regard, CCB monotherapy in those with stage 1 hypertension reduced renal and cardiovascular complications compared to other drug classes. Combination therapy with CCBs and angiotensin receptor blockers or angiotensin-converting enzyme inhibitors has been shown to be an effective dual therapy based on recent meta-analyses. This article is a review of calcium channel blockers and their use in treating hypertension with some updated and recent information on studies that have re-examined their use. As for new information, we tried to include some information from recent studies on hypertensive treatment involving calcium channel blockers.

Schlagwörter

Stichwörter der Autor:innen

angiotensin receptor blockersangiotensin-converting enzyme inhibitorscalcium channel blockerhypertension

Autor:innen und Institutionen

  • School of Medicine, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.
  • School of Medicine, St. George's University, True Blue, West Indies FZ818, Grenada.
  • Department of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.
  • Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA.
  • Departments of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.

ORCID-Profile: Hannah R Meyer, Adam M Kaye, Sahar Shekoohi, Alan D Kaye

Zitieren

APA

Jones, K. E., Hayden, S. L., Meyer, H. R., Sandoz, J. L., Arata, W. H., Dufrene, K., Ballaera, C., Lopez Torres, Y., Griffin, P., Kaye, A. M., Shekoohi, S., & Kaye, A. D. (2024). The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations. Current Issues in Molecular Biology, 46(7), 6315-6327. https://doi.org/10.3390/cimb46070377

Vancouver

Jones KE, Hayden SL, Meyer HR, Sandoz JL, Arata WH, Dufrene K, et al. The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations. Current Issues in Molecular Biology. 2024;46(7):6315-6327. doi:10.3390/cimb46070377

BibTeX
@article{Jones2024,
  author = {Jones, Kamryn E and Hayden, Shaun L and Meyer, Hannah R and Sandoz, Jillian L and Arata, William H and Dufrene, Kylie and Ballaera, Corrado and Lopez Torres, Yair and Griffin, Patricia and Kaye, Adam M and Shekoohi, Sahar and Kaye, Alan D},
  title = {The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations},
  journal = {Current Issues in Molecular Biology},
  year = {2024},
  volume = {46},
  number = {7},
  pages = {6315--6327},
  doi = {10.3390/cimb46070377}
}
Kostenlos starten →